




Charts to the statement at the Annual Shareholders' Meeting in Essen (Germany)

on May 25, 2022 · 10:00 a.m.

Christian Kullmann, Chairman of the Executive Board of Evonik Industries AG

In 2021 we wanted to grow and have clearly exceeded 2020 and 2019

External Sales	2021 vs. 2020	Adjusted net income
€14,955 million	 23 %	€986 million
Adjusted EBITDA		Adjusted earnings per share
€2,383 million	 25 %	
Free Cash Flow		
€950 million	 22 %	€2.12

Next Generation Evonik

The next phase of our strategic transformation

Three major strategic levers...


... with sustainability fully integrated ...

... delivering on ambitious targets

Portfolio

Innovation

Culture



Mid-term financial targets

- Organic growth >4%
- EBITDA margin 18–20%
- ROCE ~11%
- Cash conversion >40%

ESG targets 2030

- >50% sales share of **NEXTGEN Solutions** ✖
- -25% CO2 emission reduction, e.g. via **NEXTGEN Technologies** ✖

Portfolio

We continue to develop consistently

Specialty Chemicals

Focus on
three growth divisions



Acquisitions

Strengthening our
sustainable businesses



Exit of Performance Materials

Performance Intermediates:

Prepare for the future with a strong partner

Functional Solutions:

Sales process started for the Luelsdorf site

Baby Care:

Separated as a legal entity since mid-2021



Innovation

Our Growth Fields right on track

Innovation Growth Fields		
		
Advanced Food Ingredients	Additive Manufacturing	Sustainable Nutrition
		
Cosmetic Solutions	Membranes	Healthcare Solutions



Sizeable sales base established in all growth fields

Above-average margin contribution

Sales contribution Innovation Growth Fields		
	Growth p.a.	Sales level
Achieved in 2021	>40%	>€ 500 million
Targets until 2025	25%	>€ 1 billion


“Next Generation Solutions”

More sales with our sustainable products

Future Mobility solutions



Additives for durability in construction



Drug Delivery Systems



Modern aquaculture solutions



1. Sales contribution of Next Generation Solutions until 2030

“Next Generation Technologies”

Our commitment for climate protection

Achievements¹ on GHG emissions' reduction

2021 > -43%

New targets² for GHG emissions scope 1&2

2030 > -25% 2050 > -100%

Integration into management compensation³

Long-term incentive
Compensation (LTI)
based on ESG targets

20%
ESG

Targeted initiatives for emission reductions

€ 700 million capital expenditures (2022–2030) ...

NEXTGEN 
Technologies

... result in > € 100 million operational savings (p.a.)

1 Net emissions (= gross emissions minus power and steam sold externally); reference year 2008; on initial -50% target by year 2025

2. Gross emissions; reference year 2021, target year 2030

3. Starting in 2023, long-term variable compensation will be determined 80% by the performance of Evonik shares and 20% by the achievement of one or more sustainability goals


Culture

How we shape our future with diversity

The world around us is becoming more complex

Diversity in the company is indispensable


Each individual contributes to and benefits from this



Gender diversity: 23% women in executive and senior management positions with women and 30% on manager level by 2023

Intercultural mix: 20% in executive and 35% in senior management positions by 2023

Increase in dividend and high dividend yield of around 4 percent



Evonik shares


Share price development 2021 and 2022

Share price development 2021

Evonik: +7%

DJ Stoxx Chemicals 600: +22%

MDAX: +14%




Share price development 2022¹

Evonik: +11%

DJ Stoxx Chemicals 600: -11%

MDAX: +19%



1. Share price development YTD until May 11, 2022

1st quarter 2021

Strong start into the year

Business development very positive in first quarter way ahead of expectations



Price increases across all divisions compensated for higher variable costs



Sales:
€4,498 million



Adjusted EBITDA:
€735 million




Adjusted earnings per share:
€0.76



2022 Outlook confirmed

Adjusted EBITDA expectations between €2.5–2.6 billion





EVONIK

Leading Beyond Chemistry